Table 1 Baseline characteristics of patients and their association with four-miRNA classifier.
HDH-CC (n = 54) | TCGA-COAD (n = 122) | |||||||
|---|---|---|---|---|---|---|---|---|
Number of patients | Low risk (%) | High risk (%) | p-value* | Number of patients | Low risk (%) | High risk (%) | p-value* | |
Age | 0.74 | 0.96 | ||||||
≤72.98 | 22 | 18 (82%) | 4 (18%) | 53 | 34 (64%) | 19 (36%) | ||
>72.98 | 32 | 25 (78%) | 7 (22%) | 69 | 44 (64%) | 25 (36%) | ||
Gender | 0.38 | 0.93 | ||||||
Women | 28 | 21 (75%) | 7 (25%) | 52 | 33 (64%) | 19 (36%) | ||
Men | 26 | 22 (85%) | 4 (15%) | 70 | 45 (64%) | 25 (36%) | ||
MMR status | 0.44 | |||||||
Deficient | 15 | 13 (87%) | 2 (13%) | — | — | — | ||
Proficient | 35 | 27 (77%) | 8 (23%) | — | — | — | ||
ND | 4 | — | — | — | — | — | ||
MSI status | 0.63 | |||||||
MSI | — | — | — | 50 | 33 (66%) | 17 (34%) | ||
MSS | — | — | — | 72 | 45 (62%) | 27 (38%) | ||
Tumor stage | 0.04 | 0.67 | ||||||
T3 | 51 | 42 (82%) | 9 (18%) | 115 | 73 (64%) | 42 (36%) | ||
T4 | 3 | 1 (33%) | 2 (67%) | 7 | 5 (71%) | 2 (29%) | ||
Differentiation | 0.19 | |||||||
Well/Moderate | 46 | 38 (83%) | 8 (17%) | — | — | — | ||
Poor | 8 | 5 (63%) | 3 (37%) | — | — | — | ||
TLN | 0.23 | 0.4 | ||||||
<12 | 5 | 5 (100%) | 0 (0%) | 13 | 11 (85%) | 2 (15%) | ||
≥12 | 49 | 38 (78%) | 11 (22%) | 96 | 60 (63%) | 36 (37%) | ||
ND | — | — | — | 13 | — | — | ||
Histology type | 0.12 | |||||||
Adenocarcinoma | 50 | 41 (82%) | 9 (18%) | — | — | — | ||
Varianta | 4 | 2 (50%) | 2 (50%) | — | — | — | ||
Recurrence | <0.001 | 0.006 | ||||||
Yes | 7 | 1 (14%) | 6 (86%) | 23 | 9 (39%) | 14 (61%) | ||
No | 47 | 42 (89%) | 5 (11%) | 99 | 69 (70%) | 30 (30%) | ||
